Geneva, Switzerland, January 25, 2018 – Abologix, a privately held swiss biotechnology company developing novel immuno-oncology products for the benefit of cancer patients has been founded in Geneva, Switzerland by Dr. Ignacio Faus, Prof. Beat Imhof (University of Geneva) and Prof. Thomas Matthes (Geneva University Hospital ).
top of page
Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...
Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization...
Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...
bottom of page
Kommentare